Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Iovance Biotherapeutics, Inc.    IOVA

IOVANCE BIOTHERAPEUTICS, INC.

(IOVA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/30/2020 07/31/2020 08/03/2020 08/04/2020 08/05/2020 Date
28.85(c) 29.07(c) 31.06(c) 30.77(c) 30.45 Last
711 722 1 149 348 1 442 887 805 279 35 677 Volume
+0.70% +0.76% +6.85% -0.93% -1.04% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -279 M - -
Net cash position 2020 648 M - -
P/E ratio 2020 -14,8x
Yield 2020 -
Sales 2021 52,1 M - -
Net income 2021 -306 M - -
Net cash position 2021 411 M - -
P/E ratio 2021 -14,2x
Yield 2021 -
Capitalization 4 545 M 4 545 M -
EV / Sales 2020 -
EV / Sales 2021 79,3x
Nbr of Employees 148
Free-Float 91,4%
More Financials
Company
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company has developed a shorter manufacturing process for Tumor infiltrating lymphocyte (TIL) therapy known as Generation 2... 
More about the company
Surperformance© ratings of Iovance Biotherapeutics, I
Trading Rating : Investor Rating : -
More Ratings
Latest news on IOVANCE BIOTHERAPEUTICS, I
07/23Iovance Biotherapeutics to Host Second Quarter 2020 Financial Results Confere..
GL
06/12IOVANCE BIOTHERAPEUTICS, INC. : Change in Directors or Principal Officers (form ..
AQ
06/09IOVANCE BIOTHERAPEUTICS, INC. : Change in Directors or Principal Officers, Submi..
AQ
06/08Iovance Biotherapeutics to Present at Upcoming June Conferences
GL
06/02IOVANCE BIOTHERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits ..
AQ
06/02Iovance Biotherapeutics, Inc. Announces Closing of $603.7 Million Common Stoc..
GL
05/29IOVANCE BIOTHERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits ..
AQ
05/29Iovance Presents Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL..
GL
05/28Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of App..
GL
05/28IOVANCE BIOTHERAPEUTICS : Reports Pivotal Cohort 4 Data for Tumor Infiltrating L..
AQ
05/27Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common St..
GL
05/27IOVANCE BIOTHERAPEUTICS, INC. : Amendments to Articles of Inc. or Bylaws; Change..
AQ
05/27Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL)..
GL
05/22IOVANCE BIOTHERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits ..
AQ
05/13Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Adv..
GL
More news
News in other languages on IOVANCE BIOTHERAPEUTICS, I
07/23Iovance Biotherapeutics to Host Second Quarter 2020 Financial Results Confere..
06/12IOVANCE BIOTHERAPEUTICS, INC. : Change in Directors or Principal Officers (form ..
06/09IOVANCE BIOTHERAPEUTICS, INC. : Change in Directors or Principal Officers, Submi..
06/08Iovance Biotherapeutics to Present at Upcoming June Conferences
06/02IOVANCE BIOTHERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits ..
More news
Chart IOVANCE BIOTHERAPEUTICS, INC.
Duration : Period :
Iovance Biotherapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IOVANCE BIOTHERAPEUTICS, I
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Average target price 46,42 $
Last Close Price 31,06 $
Spread / Highest target 109%
Spread / Average Target 49,4%
Spread / Lowest Target -0,19%
EPS Revisions
Managers
NameTitle
Maria Fardis President, Chief Executive Officer & Director
Iain David Dukes Chairman
Michael C. Swartzburg Chief Financial & Accounting Officer
Friedrich Graf Finckenstein Chief Medical Officer
Merrill A. McPeak Independent Director
Sector and Competitors